Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Control de enfermedades neurodegenerativas con derivados de benzotiazol-benzamida

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20180918003
Publicado:
27/09/2018
Caducidad:
28/09/2019
Resumen:
Un centro español de investigación pública ha desarrollado un grupo de compuestos heterocíclicos derivados de un núcleo estructural privilegiado con capacidad de inhibir la enzima LRRK2. Esta actividad inhibitoria hace que sean útiles en el tratamiento de enfermedades neurodegenerativas afectadas por esta enzima, entre las que destaca la enfermedad de Parkinson y la enfermedad de Alzheimer. Estas moléculas son capaces de atravesar la barrera hematoencefálica, lo que supone una ventaja adicional de los compuestos cuando se utilizan en tratamientos terapéuticos de enfermedades relacionadas con el sistema nervioso central. El centro de investigación busca compañías farmacéuticas interesadas en el desarrollo y comercialización de estos compuestos bajo licencia de patente.

Details

Tittle:
Control of neurodegenerative diseases with benzothiazole-benzamide derivatives.
Summary:
A Spanish Research Public Organization has developed a group of heterocyclic compounds derived from a privileged structural nucleus with the capacity to inhibit the LRRK2 enzyme. This inhibitory activity makes them useful in the treatment of neurodegenerative diseases affected by this enzyme, among which Parkinson´s disease and Alzheimer´s disease stand out. Pharmaceutical companies interested in the development and commercialization of these compounds under a patent license are sought.
Description:
Neurodegenerative diseases, currently increasing, show as a common characteristic a progressive loss of neurons in specific regions of the nervous system and the deterioration of cognitive and motor functions. The lack of a specific treatment in most of them leads to the continuous search for new therapeutic targets.
LRRK2 is a protein that has been classified as a member of the ROCO superfamily (Ras-like GTPase). Its physiological role is not well determined, but it has become an interesting target for neurodegenerative diseases, especially Parkinson´s disease. It may also be related to other pathologies in which the tau protein is affected, as well as to the inflammatory response, oxidative stress, synaptic and mitochondrial dysfunctions and neurogenesis in adults. Because of the interest in LRRK2 as a therapeutic target for neurodegenerative diseases, inhibitors of this enzyme have been found that would be potential treatments, but most of these compounds present the difficulty of not crossing the blood-brain barrier or being less selective towards other protein kinases, which is an important problem in drug candidates for the treatment of diseases of the central nervous system (CNS).
Researchers have developed compounds with a privileged structural core that makes them selective inhibitors of the LRRK2 protein, and capable of crossing the blood-brain barrier. The authors have shown the neurogenic activity of these compounds as well as their involvement in neuroprotection against the phosphorylation of the tau protein.
The Spanish research center has a broad experience in developing novel compounds to be tested as potential candidates to treat neurodegenerative pathologies.

The Spanish research center is searching for a company interested in the development and commercialization of these novel compounds under a license agreement.

The compounds have only been tested at a laboratory scale, therefore some further development might be needed and the Spanish research center could collaborate with the company in that project.
Advantages and Innovations:
These molecules can cross the blood-brain barrier, which is an additional advantage of the compounds when used in therapeutic treatments of diseases related to the central nervous system.

They can be presented in the most suitable pharmaceutical formulation for each treatment.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patent application

Partner sought

Type and Role of Partner Sought:

Industrial partners from pharmaceutical industry are being sought to develop and commercialize the compounds through a patent licence agreement.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos